These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 16442924

  • 1. Effects of clopidogrel on soluble CD40 ligand and on high-sensitivity C-reactive protein in patients with stable coronary artery disease.
    Azar RR, Kassab R, Zoghbi A, Aboujaoudé S, El-Osta H, Ghorra P, Germanos M, Salamé E.
    Am Heart J; 2006 Feb; 151(2):521.e1-521.e4. PubMed ID: 16442924
    [Abstract] [Full Text] [Related]

  • 2. Randomized comparison of the effects of ASA plus clopidogrel versus ASA alone on early platelet activation in acute coronary syndromes with elevated high-sensitivity C-reactive protein and soluble CD40 ligand levels.
    Vavuranakis M, Latsios G, Aggelis D, Bosinakou I, Karambelas I, Tousoulis D, Toutouzas K, Stefanadis C.
    Clin Ther; 2006 Jun; 28(6):860-71. PubMed ID: 16860169
    [Abstract] [Full Text] [Related]

  • 3. Anti-inflammatory effects of clopidogrel intake in renal transplant patients: effects on platelet-leukocyte interactions, platelet CD40 ligand expression, and proinflammatory biomarkers.
    Graff J, Harder S, Wahl O, Scheuermann EH, Gossmann J.
    Clin Pharmacol Ther; 2005 Nov; 78(5):468-76. PubMed ID: 16321613
    [Abstract] [Full Text] [Related]

  • 4. Effect of aspirin plus clopidogrel on inflammatory markers in patients with non-ST-segment elevation acute coronary syndrome.
    Chen YG, Xu F, Zhang Y, Ji QS, Sun Y, Lü RJ, Li RJ.
    Chin Med J (Engl); 2006 Jan 05; 119(1):32-6. PubMed ID: 16454979
    [Abstract] [Full Text] [Related]

  • 5. Relationship between baseline inflammatory markers, antiplatelet therapy, and adverse cardiac events after percutaneous coronary intervention: an analysis from the clopidogrel for the reduction of events during observation trial.
    Dosh K, Berger PB, Marso S, van Lente F, Brennan DM, Charnigo R, Topol EJ, Steinhubl S.
    Circ Cardiovasc Interv; 2009 Dec 05; 2(6):503-12. PubMed ID: 20031767
    [Abstract] [Full Text] [Related]

  • 6. Thrombin formation and platelet activation at the site of vascular injury in patients with coronary artery disease treated with clopidogrel combined with aspirin.
    Undas A, Stepień E, Branicka A, Wołkow P, Zmudka K, Tracz W.
    Kardiol Pol; 2009 Jun 05; 67(6):591-8. PubMed ID: 19618315
    [Abstract] [Full Text] [Related]

  • 7. Clopidogrel-mediated reduction of circulating tissue factor in patients with stable coronary artery disease.
    Stellbaum C, Willich T, Boltzen U, Ayral Y, Szotowski B, Piorkowski M, Schultheiss HP, Rauch U.
    Eur J Haematol; 2007 Apr 05; 78(4):347-52. PubMed ID: 17331131
    [Abstract] [Full Text] [Related]

  • 8. Homocysteine-lowering therapy does not affect inflammatory markers of atherosclerosis in patients with stable coronary artery disease.
    Bleie Ø, Semb AG, Grundt H, Nordrehaug JE, Vollset SE, Ueland PM, Nilsen DW, Bakken AM, Refsum H, Nygård OK.
    J Intern Med; 2007 Aug 05; 262(2):244-53. PubMed ID: 17645592
    [Abstract] [Full Text] [Related]

  • 9. Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study.
    Storey RF, Bliden KP, Patil SB, Karunakaran A, Ecob R, Butler K, Teng R, Wei C, Tantry US, Gurbel PA, ONSET/OFFSET Investigators.
    J Am Coll Cardiol; 2010 Jul 13; 56(3):185-93. PubMed ID: 20620737
    [Abstract] [Full Text] [Related]

  • 10. Analysis of platelet alpha2-adrenergic receptor activity in stable coronary artery disease patients on dual antiplatelet therapy.
    Béres BJ, Tóth-Zsámboki E, Vargová K, László A, Masszi T, Kerecsen G, Préda I, Kiss RG.
    Thromb Haemost; 2008 Nov 13; 100(5):829-38. PubMed ID: 18989527
    [Abstract] [Full Text] [Related]

  • 11. Effect of clopidogrel withdrawal on platelet reactivity and vascular inflammatory biomarkers 1 year after drug-eluting stent implantation: results of the prospective, single-centre CESSATION study.
    Sambu N, Dent H, Englyst N, Warner TD, Leadbeater P, Roderick P, Gray H, Simpson I, Corbett S, Calver A, Morgan J, Curzen N.
    Heart; 2011 Oct 13; 97(20):1661-7. PubMed ID: 21795297
    [Abstract] [Full Text] [Related]

  • 12. Benefits and risks of clopidogrel use in patients with coronary artery disease: evidence from randomized studies and registries.
    Motovska Z, Kala P.
    Clin Ther; 2008 Oct 13; 30 Pt 2():2191-202. PubMed ID: 19281914
    [Abstract] [Full Text] [Related]

  • 13. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study.
    Gurbel PA, Bliden KP, Butler K, Tantry US, Gesheff T, Wei C, Teng R, Antonino MJ, Patil SB, Karunakaran A, Kereiakes DJ, Parris C, Purdy D, Wilson V, Ledley GS, Storey RF.
    Circulation; 2009 Dec 22; 120(25):2577-85. PubMed ID: 19923168
    [Abstract] [Full Text] [Related]

  • 14. Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial.
    Serebruany VL, Malinin AI, Pokov AN, Hanley DF.
    Clin Ther; 2008 Feb 22; 30(2):249-59. PubMed ID: 18343263
    [Abstract] [Full Text] [Related]

  • 15. The presence of metabolic syndrome is independently associated with elevated serum CD40 ligand and disease severity in patients with symptomatic coronary artery disease.
    Lee WL, Lee WJ, Chen YT, Liu TJ, Liang KW, Ting CT, Huey-Herng Sheu W.
    Metabolism; 2006 Aug 22; 55(8):1029-34. PubMed ID: 16839837
    [Abstract] [Full Text] [Related]

  • 16. Variability of C-reactive protein levels among patients with stable coronary artery disease and on statin therapy.
    Blum A, Costello R, Samsel L, Zalos G, McCoy P, Csako G, Waclawiw MA, Cannon RO.
    Isr Med Assoc J; 2009 Oct 22; 11(10):602-5. PubMed ID: 20077946
    [Abstract] [Full Text] [Related]

  • 17. Effects of tirofiban and statins on high-sensitivity C-reactive protein, interleukin-6, and soluble CD40 ligand following percutaneous coronary interventions in patients with stable coronary artery disease.
    Azar RR, Badaoui G, Sarkis A, Kassab R, Salamé E, Klaymé S, Naman R, Germanos M.
    Am J Cardiol; 2005 Jan 15; 95(2):236-40. PubMed ID: 15642557
    [Abstract] [Full Text] [Related]

  • 18. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.
    Mohler ER, Ballantyne CM, Davidson MH, Hanefeld M, Ruilope LM, Johnson JL, Zalewski A, Darapladib Investigators.
    J Am Coll Cardiol; 2008 Apr 29; 51(17):1632-41. PubMed ID: 18436114
    [Abstract] [Full Text] [Related]

  • 19. Effect of atorvastatin on circulating proinflammatory T-lymphocyte subsets and soluble CD40 ligand in patients with stable coronary artery disease--a randomized, placebo-controlled study.
    Alber HF, Frick M, Suessenbacher A, Doerler J, Schirmer M, Stocker EM, Dichtl W, Pachinger O, Weidinger F.
    Am Heart J; 2006 Jan 29; 151(1):139. PubMed ID: 16368305
    [Abstract] [Full Text] [Related]

  • 20. The levels of circulating markers of atherosclerosis and inflammation in subjects with different degrees of body mass index: Soluble CD40 ligand and high-sensitivity C-reactive protein.
    Guldiken S, Demir M, Arikan E, Turgut B, Azcan S, Gerenli M, Tugrul A.
    Thromb Res; 2007 Jan 29; 119(1):79-84. PubMed ID: 16476470
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.